• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Adare Pharma Solutions

    Quotient Sciences

    Aphena Pharma Solutions

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Emergent BioSolutions

    Quotient Sciences

    Syngene

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CDMOs On The Rise

    Tracking growth and strategies in the CDMO business

    CDMOs On The Rise
    Related CONTENT
    • Asymchem
    • Avara Pharmaceutical Services
    • Mogene
    • Zile Bonbons
    • Grand River Aseptic Manufacturing
    Michel Le Bars, Managing Partner, Kurmann Partners AGe01.25.19
    The pharma outsourcing market promises robust and attractive growth although with differences in growth rate and profitability by market segment. Are there differentiating strategies to capture the growth of the pharma contract manufacturing market? How can pharmaceutical companies take advantage of the on-going consolidation?

    “The whole is greater than the sum of its parts”
    Aristotle’s quote finds some resonance when it comes to assessing the global market for pharmaceutical outsourcing. Adding the sales estimates of the contract development manufacturing organizations (CDMOs) and contract research organizations (CROs) results in a market size greater than $120 billion, but it is likely far from reflecting its full potential. For 2017, the contract manufacturing market alone is estimated at about $70-75 billion including clinical supplies, active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs).

    The share of the API contract manufacturing (merchant) market is roughly $50 billion, which is still less than 40% of the global synthetic API market, comprising advanced intermediates and chemically synthesized APIs. Indeed, captive use, i.e. pharmaceutical companies’ production for their own needs, still accounts for a larger proportion of total API supply. At a time when larger pharmaceutical companies are focusing on reducing their operational expenses and prioritizing capital investments on their most innovative products, this in-house capacity represents in itself a large reservoir adding to the growth potential of the CDMO industry.

    Additional factors providing a solid foundation for growth include worldwide improvement in access to medicines, in particular for generic drugs. Innovative and targeted therapies constitute another growth driver and not only for larger molecules. For instance, the small molecule API market benefits from favorable dynamics fueled by strong drug approval rates by the FDA—46 novel drugs including 34 small molecules in 2017—an increasing number of molecules in clinical phases and increasing outsourcing by the pharmaceutical companies.

    These factors contribute to promising growth of 6-7% per year across all geographies resulting in outsourced manufacturing valued at above $100 billion by 2022.

    Capturing the value in CDMO services
    The main three segments in the CDMO value chain present different growth patterns; for companies such as Patheon, Lonza or AMRI, the revenue growth rates range:

    • single digit for conventional FDFs (e.g. tablets); as opposed to:
    • between 10-20% for drug development services; or
    • between 15-25% for more complex FDFs (e.g. injectables) and API production.

    However, any assessment of the profitability requires a finer sub-segmentation. For instance, the API market attractiveness is a result of the increasing global API demand and the limited number of contract manufacturing organizations (CMOs) with differentiated capabilities, capacity and scale. On the one hand, large volume businesses—typically commodity APIs mainly exported from Asia—return lower margins (3-4%). On the other hand, custom synthesis is a much more profitable business based on the exclusive know-how of the supplier, often integrated with contract research and drug discovery activity for innovative APIs. Many European API manufacturers enjoy 20-25% EBITDA margin. High-potency APIs is another very valuable segment but also very demanding, process-wise, due to stringent containment requirements.

    Similarly, in the FDF segment, the CDMOs that have followed a value-driven strategy—versus a volume approach—by adding services or investing in more complex technologies deliver higher returns (e.g. Catalent).
    How can CDMOs achieve differentiation?

    The last 12 months have seen a series of capital investment and acquisition announcements aiming at realizing differentiating strategies, such as gaining scale, establishing a specialist position or vertically integrating to offer a one-stop-shop.

    Gaining scale
    Successfully gaining scale requires outstanding execution. Lean initiatives throughout the organization are needed to achieve operational excellence, reduced complexity and competitive costs per unit. More conventional technologies may be adequate vehicles for growth as long as the entire organization shares this excellence mindset (e.g. commercial teams bring in relevant scalable volumes and manufacturing teams maximize capacity outputs with low waste levels).

    Another component of this strategy is geographic expansion, but under the condition of getting sufficient critical mass. We estimate the minimum revenue per FDF site should be at least $50 million in order to leverage economies of scale—and at $30 million for an API site. This seems to be the strategic path followed by Avara Pharmaceutical Services, a fairly recent entrant into the CDMO market, which has built its network over the last three years by acquiring businesses from Big Pharma such as UCB, Astra Zeneca and Pfizer. Its latest acquisition is the largest sterile manufacturing facility for injectable medicines in Canada from Sandoz as part of a continuing expansion of its global footprint.

    Establishing a “specialist” position
    Developing expertise in selected advanced technologies usually leads to higher profitability as illustrated by specialized API CMOs (e.g. steroids or hormones) which exhibit higher EBITDA margin, typically in the 20-25% range. 

    On the FDF CMO side, Recipharm’s Solids and Others segment delivers 15.2% EBITDA margin when, in comparison, its Sterile Liquids segment including vials and ampoules, lyophilizates and blow-fill-seal products delivers close to 20%. Its Sterile Liquid segment is built on technology-driven acquisitions such as Nitin Lifesciences, Corvette Pharmaceuticals, Mitim or Alcon’s Kaysersberg plant.

    The sterile manufacturing demand remains strong and capacity shortage is leading Pharma companies to expand their in-house capacities (e.g Pfizer, Aspen or J&J). It also motivates CDMOs (e.g Grand River Aseptic Manufacturing, Novasep or Fujifilm) to expand their facilities and to invest in high-speed, latest isolator manufacturing technology and fully integrated packaging lines.

    Is there a sweet spot? A significant proportion of new drugs in development are targeting more specialized medicines, with immuno-oncology being an area of intense activity. Hence, combining development capabilities, high potency API production and sterile liquid formulation dosages is certainly an attractive playground.

    Offering a one-stop-shop
    This model requires vertical integration and is limited to the major players and consolidators.

    The acquisition of Capsugel was a major milestone in Lonza Pharma & Biotech’s strategic plan to become a provider of one-stop-shop services and solutions for its customers. The takeover of Micro-Macinazione is complementing its micronization capabilities to meet the growing demand for improved bioavailability and efficacy of drug products.

    Similarly, Catalent’s $133 million deal for Juniper Pharmaceutical further supports its strategic goal to be the most comprehensive partner for pharmaceutical innovators adding high-end, fee-for-service development and clinical trials manufacturing to its offering.

    The one-stop-shop model seems clearly beneficial to smaller biotechs and virtual pharma companies with biologics needs. Big pharmaceutical companies, in which development and procurement teams usually follow different reporting lines, remain to be convinced.

    Pharma companies may take advantage of the players’ M&A appetite
    The last five years have seen the emergence of larger players through consolidation or acquisition of pharma sites: Aenova or Catalent have favored targeting CDMOs as illustrated by Catalent’s acquisition of Cook Pharmica. Delpharm, Famar, Corden, Patheon, or more recently, Avara, have been identified as the usual suspects when it comes to bidding for Pharma divestments. The M&A activity remains intense for FDFs capabilities as illustrated by Recipharm’s recent acquisition of Sanofi’s inhalation business. There have been fewer divestments in the API area, but a consolidation is also taking place in that segment driven by European-based companies backed by private equity groups: Spanish Suanfarma, Italian P&R Holding (including Olon and Fidia with sales above €750mn) or French Novacap (reaching sales of $1 billion since the acquisition of PCAS and PCI Synthesis).

    In addition, we observe an increasing interest for both facilities and products of credible Korean, Chinese and Indian CMOs or generic companies as well as other associations of western financial investors supported by operating vehicles, all pursuing a strategy to become integrated generic companies.

    As the larger pharma companies reshuffle their product portfolio to focus on selected therapeutic areas, they also prioritize in-house investments on their most innovative products, e.g. Novartis with its investment into a cell- and gene-therapy manufacturing unit at their site in Stein, Switzerland.

    The pharma companies can benefit by divesting manufacturing operations together with products before their patent expiry. This requires internal competencies to better manage product lifecycle, anticipate capacity planning and to engage early enough in a transaction process.

    Many larger pharma companies clearly state that acting as a CMO does not fit with their strategy and recognize the divestment decision is still a tough one. The valuation expectations need to account for many variables: the commercial long-term landscape, future CAPEX constraints, operational efficiency in comparison to best-in class and true market value of the assets. It also requires M&A advisory that not only masters the transaction process from carving-out to closing, but importantly understands the full span of the value chain and achievable synergies. 



     
    Michel Le Bars is Managing Partner at Kurmann Partners AG, an M&A advisory boutique based in Basel, Switzerland and specialized in the Pharma & Medtech industries. He was previously in charge of business development for EMEA at Merck & Co / MSD. He can be reached at www.kurmannpartners.com.
    Related Searches
    • Clinical Trials
    • novartis
    • contract manufacturing organizations
    • Aseptic
    Suggested For You
    Asymchem Asymchem
    Avara Pharmaceutical Services Avara Pharmaceutical Services
    Mogene Mogene
    Zile Bonbons Zile Bonbons
    Grand River Aseptic Manufacturing Grand River Aseptic Manufacturing
    Recipharm Recipharm
    Vetio Animal Health Vetio Animal Health
    Digitization: Pharma 4.0 Digitization: Pharma 4.0
    Thousand Oaks Expands Bio CDMO Biz Thousand Oaks Expands Bio CDMO Biz
    3P Biopharmaceuticals Completes Facility Expansion 3P Biopharmaceuticals Completes Facility Expansion
    Corden Pharma Corden Pharma
    Injectables Go Deeper Injectables Go Deeper
     Dedicated to Excellence Dedicated to Excellence
    Metrics Contract Services Metrics Contract Services
    Getting to First-in-Human Clinical Trials Getting to First-in-Human Clinical Trials

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • Drug Development | Preclinical Outsourcing
      Preclinical Planning for Successful Drug Development

      Preclinical Planning for Successful Drug Development

      When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.
      Mingyi Trimble, WuXi AppTec 09.09.20


    • APIs | Drug Development | Risk Management
      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.
      Sarah Bethune, Cambrex 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Drug Development | Regulatory Affairs
      Guidelines in Toxicology: A Blessing and a Curse

      Guidelines in Toxicology: A Blessing and a Curse

      A look at the evolution of drug development regulatory guides.
      Sarah Gould, Senior Principal Scientific Advisor, Charles River 09.16.19


    • Drug Development
      Flex Your Outsourcing Model to Maximize Drug Development

      Flex Your Outsourcing Model to Maximize Drug Development

      How to choose—and optimize—combinations of service models to fit your needs.
      Timothy King, Executive Director, Functional Service Partnerships (FSP), PPD 09.16.19

    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Drug Development
      Improving Your Development Program

      Improving Your Development Program

      Seven lab science trends driving the future of drug development.
      Jenifer Vija, Liam Moran, Chris Loosbroock and Eric Snyder, Charles River 05.07.19


    • Drug Development
      Technical Advantages of Continuous Flow Chemical Synthesis

      Technical Advantages of Continuous Flow Chemical Synthesis

      Continuous flow chemistry is known for its ability to handle hazardous reactions safely, but can also unlock many other technological benefits.
      Shawn Conway, Engineering R&D Director, Cambrex High Point 04.05.19

    • Drug Development | Preclinical Outsourcing
      Early Development Trends

      Early Development Trends

      Catalent’s president of oral drug delivery, Jonathan Arnold, talks trends and challenges in the early phases of drug development.
      Tim Wright, Editor, Contract Pharma 03.06.19

    • Drug Development
      Future Trends in the CDMO Space

      Future Trends in the CDMO Space

      And how to navigate them for successful drug development
      Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma 01.25.19


    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    • Drug Development
      Streamlining Drug Development:

      Streamlining Drug Development:

      Four key takeaways from Veeva’s 2018 R&D Summit
      Henry Levy, General Manager of Vault CDMS, Veeva Systems 11.13.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Executive Moves: Novavax
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Ensuring Pharma Manufacturing Quality
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login